These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 19427998)

  • 21. The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling.
    Warshamana-Greene GS; Litz J; Buchdunger E; Hofmann F; García-Echeverría C; Krystal GW
    Mol Cancer Ther; 2004 May; 3(5):527-35. PubMed ID: 15141010
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Camptothecin acts synergistically with imatinib and overcomes imatinib resistance through Bcr-Abl independence in human K562 cells.
    Ju DS; Kim MJ; Bae JH; Song HS; Chung BS; Lee MK; Kang CD; Lee HS; Kim DW; Kim SH
    Cancer Lett; 2007 Jul; 252(1):75-85. PubMed ID: 17223257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells.
    Thiesing JT; Ohno-Jones S; Kolibaba KS; Druker BJ
    Blood; 2000 Nov; 96(9):3195-9. PubMed ID: 11050003
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The influence of imatinib mesylate (STI571) used alone or in combination with purine nucleoside analogues on the normal and chronic myelogenous leukaemia progenitor cells in vitro.
    Korycka A; Robak T
    Leuk Lymphoma; 2003 Sep; 44(9):1549-55. PubMed ID: 14565659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNA damage and repair in BCR/ABL-expressing cells after combined action of idarubicin, STI571 and amifostine.
    Blasiak J; Gloc E; Pertyński T; Drzewoski J
    Anticancer Drugs; 2002 Nov; 13(10):1055-60. PubMed ID: 12439339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia.
    La Rosée P; Johnson K; O'Dwyer ME; Druker BJ
    Exp Hematol; 2002 Jul; 30(7):729-37. PubMed ID: 12135670
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Synergistic inhibitory effect of STI571 in combination with arsenic trioxide on a multidrug-resistant leukemia cell line expressing bcr-abl].
    Chen L; Wang JM; Xu XP; Gao L; Fei XH; Lou JW; Huang ZX
    Zhonghua Zhong Liu Za Zhi; 2004 Sep; 26(9):535-8. PubMed ID: 15555283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [STI571 enhances the effect of arsenic trioxide and Velcade on bcr/abl+-CD34+ cell proliferation and apoptosis].
    Li CY; Meng FY; Sun QX; Fu YB; Li L; Yi ZS; Song LL
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Nov; 27(11):1665-9. PubMed ID: 18024285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.
    Uehara H; Kim SJ; Karashima T; Shepherd DL; Fan D; Tsan R; Killion JJ; Logothetis C; Mathew P; Fidler IJ
    J Natl Cancer Inst; 2003 Mar; 95(6):458-70. PubMed ID: 12644539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. STI571 as a potent inhibitor of growth and invasiveness of human epithelial breast cancer cells.
    Roussidis AE; Mitropoulou TN; Theocharis AD; Kiamouris C; Papadopoulos S; Kletsas D; Karamanos NK
    Anticancer Res; 2004; 24(3a):1445-7. PubMed ID: 15274308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of cell survival and invasive potential of colorectal carcinoma cells by the tyrosine kinase inhibitor STI571.
    Bellone G; Ferrero D; Carbone A; De Quadros MR; Gramigni C; Prati A; Davidson W; Mioli P; Dughera L; Emanuelli G; Rodeck U
    Cancer Biol Ther; 2004 Apr; 3(4):385-92. PubMed ID: 14726674
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Involvement of Akt kinase in the action of STI571 on chronic myelogenous leukemia cells.
    Kawauchi K; Ogasawara T; Yasuyama M; Ohkawa Si
    Blood Cells Mol Dis; 2003; 31(1):11-7. PubMed ID: 12850478
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aminopeptidase inhibitors inhibit proliferation and induce apoptosis of K562 and STI571-resistant K562 cell lines through the MAPK and GSK-3beta pathways.
    Sawafuji K; Miyakawa Y; Weisberg E; Griffin JD; Ikeda Y; Kizaki M
    Leuk Lymphoma; 2003 Nov; 44(11):1987-96. PubMed ID: 14738154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
    Yu C; Rahmani M; Almenara J; Subler M; Krystal G; Conrad D; Varticovski L; Dent P; Grant S
    Cancer Res; 2003 May; 63(9):2118-26. PubMed ID: 12727828
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of chronic myeloid leukemia cells with imatinib (STI571) impairs p53 accumulation in response to DNA damage.
    Goldberg Z; Levav Y; Krichevsky S; Fibach E; Haupt Y
    Cell Cycle; 2004 Sep; 3(9):1188-95. PubMed ID: 15467443
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro.
    Zhang P; Gao WY; Turner S; Ducatman BS
    Mol Cancer; 2003 Jan; 2():1. PubMed ID: 12537587
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.
    Donato NJ; Wu JY; Stapley J; Gallick G; Lin H; Arlinghaus R; Talpaz M
    Blood; 2003 Jan; 101(2):690-8. PubMed ID: 12509383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
    Yu C; Rahmani M; Conrad D; Subler M; Dent P; Grant S
    Blood; 2003 Nov; 102(10):3765-74. PubMed ID: 12893773
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imatinib mesylate induction of ROS-dependent apoptosis in melanoma B16F0 cells.
    Chang SP; Shen SC; Lee WR; Yang LL; Chen YC
    J Dermatol Sci; 2011 Jun; 62(3):183-91. PubMed ID: 21482077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor].
    Nakajima M; Toga W
    Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):482-90. PubMed ID: 14639002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.